← Back to news

Markets

Silver Just Hit A 'Now Or Never' Level: Which Miner Is Best Positioned If The Metal Bounces?

Y

Apple Price Hikes Sent AAPL Stock Falling. They May Not Even Matter in the Long Term.

Y

Securitize Lists on NYSE as SECZ: Backed by $400M Raise and BlackRock BUIDL

Y

Cathie Wood Makes Fresh Bullish Bitcoin Call — Just Months After $1.5M Prediction

Y

Wall Street Futures Edge Lower as Investors Lock In Profits After Record Rally: Dow Jones, S&P, Nasdaq

Y

XRPL Lending Protocol Testing Opens as Validator Vote on XLS-65 and XLS-66 Continues

Y

The John Rogers Contrarian Playbook: How Envista, MSG Entertainment, and Smucker Stack Up for Retirement Investors

Y

Where Will Tesla Stock Be in 5 Years?

Y

Is MapLight Therapeutics, Inc. (MPLT) Stock a Biotech Opportunity Ahead of the ZEPHYR Trial Readout?

Y

Is Rhythm Pharmaceuticals, Inc. (RYTM) Stock Poised for Growth After Encouraging Setmelanotide Trial Results?

Y

MoonLake Immunotherapeutics (MLTX) Outlook Strengthens as Analysts See Major Opportunity in Hidradenitis Suppurativa

Y

Is Definium Therapeutics, Inc. (DFTX) Stock Poised for Further Gains After Positive Emerge Trial Update?

Y

Is Zymeworks Inc. (ZYME) Stock an Undervalued Biotech Opportunity With Oncology Growth Ahead?

Y

Is Celldex Therapeutics, Inc. (CLDX) Stock Positioned for Growth Ahead of Potential 2027 Approval?

Y

Nurix Therapeutics, Inc. (NRIX) Price Target Raised to $33 on Roche Partnership Value

Y

Is Jade Biosciences, Inc. (JBIO) Stock a Rising Biotech Opportunity in the $20B IgA Nephropathy Market?

Y

Why Ascentage Pharma Group Internat (AAPG) Is Gaining Attention in Cancer Drug Development

Y

Is Medicus Pharma Ltd. (MDCX) Stock Gaining Momentum With Innovative Skin Cancer Treatment Technology?

Y

Is High Tide Inc. (HITI) Stock Turning Into a Cannabis Growth Story After Record Quarterly Results?

Y

Why Pfizer Could Prove to Be an Underrated GLP-1 Stock

Y

Meet the ETF That Beat the S&P 500 for Over 20 Years -- and History Suggests It's Ready to Pop Again

Y

Why Split With Waymo In Phoenix Could 'Weigh On' Uber Stock

Y

Drinks companies hit out at Germany’s sugar tax plans

Y

Disney $50M antitrust settlement: how to file a claim

Y

EchoStar prepares Dish DBS bankruptcy filing

Y

Maintenance staffing remains multifamily’s biggest labor challenge

Y

Teledyne Technologies (TDY) Reported Robust Organic Growth in Q1

Y

Why The Secret CFO calls this finance leader ‘the most AI-pilled CFO’

Y

Cooke nets Mowi salmon farms in Canada

Y

Can Lifecore Biomedical, Inc. (LFCR) Unlock Long-Term Value Through Expanding Biopharma Collaborations?

Y

Is Takeda Pharmaceutical Company Limited (TAK) Stock Positioned for Growth After Strong LATITUDE Atlas Study Data?

Y

Akebia Therapeutics, Inc. (AKBA) Strengthens Vafseo Patent Protection Through 2036

Y

GSK plc (GSK) Launches Tender Offer to Acquire Nuvalent Inc. for $124 Per Share

Y

3 Dividend Stocks Worth Buying More of While the Market Is Distracted

Y

Is Amylyx Pharmaceuticals, Inc. (AMLX) Stock Ready for a Breakout Ahead of Key LUCIDITY Trial Data?

Y

Microsoft Heads for Biggest Monthly Loss Since Dot-Com Burst

Y

Is BioAge Labs, Inc. (BIOA) Stock Positioned for Growth With New Phase 2 Cardiovascular Study Initiation?

Y

Comcast's NBCU split makes Wall Street's math easier

Y

Can Organon & Co. (OGN)’s MIUDELLA Launch Become a Major Driver in Women’s Health Markets?

Y

Is Xeris Biopharma Holdings, Inc. (XERS) Stock Positioned for Long-Term Growth With Extended Keveyis Exclusivity?

Y

Is Teva Pharmaceutical Industries Limited (TEVA) Stock Undervalued After Recent Pullback and Vitiligo Program Update?

Y

Warren Buffett Says This ETF Is Perfect for Everyday Investors

Y

Is Bristol-Myers Squibb Company (BMY) Stock at Risk From Proposed Medicare Drug Price Negotiation Updates?

Y

Is Caris Life Sciences, Inc. (CAI) Stock Positioned for Growth With AI-Driven Precision Medicine Expansion?

Y

Is BeOne Medicines AG (ONC) Stock Positioned for Growth After Encouraging ASCO Cancer Data?

Y

Zai Lab Limited (ZLAB) Gains EMA Orphan Drug Designation for DLL3-Targeting Cancer Therapy

Y

Despite Dropping 26% This Year, Microsoft is a No-Brainer Buy

Y

Is Tyra Biosciences, Inc. (TYRA) Stock a Biotech Opportunity Ahead of Key SURF302 Trial Data?

Y

Inflation in Eurozone’s Biggest Economies Cools More Than Expected

Y

Is Syndax Pharmaceuticals, Inc. (SNDX) Stock Still a Biotech Opportunity After Revised AML Market Estimates?

Y